

Sister Study Ovarian, Fallopian Tube, and Peritoneal Cancer Outcomes (Any Behavior)¹ and Characteristics: Data Release 11.1²

	N	% of cohort
Total Cases³	533	1.0
Timing, Behavior, and Site	N	% of cases
Baseline	207	38.8
Invasive	203	38.1
Ovary	195	36.6
Fallopian tube	3	0.6
Unknown ⁴	5	0.9
<i>In situ</i> – Peritoneum	1	0.2
Uncertain behavior – Ovary	3	0.6
Unknown timing ⁵ – Invasive – Ovary	16	3.0
Incident	310	58.2
Invasive	292	54.8
Ovary	238	44.7
Fallopian tube	22	4.1
Peritoneum ⁶	13	2.4
Unknown ⁷	19	3.6
Uncertain behavior	18	3.4
Ovary	17	3.2
Broad Ligament	1	0.2
Incident	310	
Race/Ethnicity⁸		
Non-Hispanic White	271	87.4
Non-Hispanic Black	23	7.4
Hispanic	9	2.9
Other	7	2.3
Age (in years) at Diagnosis⁹		
Under 50	18	5.8
50-64	140	45.2
65 and older	152	49.0
Diagnosis Confirmation¹⁰		
Medical	196	63.2
NDI Plus or death certificate only	43	13.9
None	71	22.9

Characteristic	N	%
Incident – Medically Confirmed	196	
Stage at Diagnosis¹¹		
I	57	30.5
II	20	10.7
III	89	47.6
IV	21	11.2
Missing, cannot stage	9	

¹ Peritoneal cancer excludes retroperitoneal site of origin. Cancer events are defined by the following ICD10 cancer codes: invasive ovary (C56), invasive fallopian tube (C57.0), invasive broad ligament (C57.1), invasive peritoneum (C48.1, C48.2, C48.8), uncertain behavior of ovary (D39.1), uncertain behavior of peritoneum (D48.4). Other ICD10 cancer codes that may be used when ovary, fallopian tube, broad ligament, or peritoneum are indicated as one of the favored primary sites: invasive female genital organ (C57.9), invasive unspecified site (C80), *in situ* female genital organ (D07.3), *in situ* other site (D09.8), uncertain behavior of female genital organ (D39.8, D39.9), unspecified behavior of genitourinary organ (D49.59).

² Data release 11.1 includes outcomes from follow-up phases that closed on or before 9/30/2021, excluding all data from participants who have withdrawn their data from the study [n=5].

³ Excludes cancer diagnoses where ovarian, fallopian tube, broad ligament, or peritoneal site of origin could not be ruled out, but none are the favored site [n=12].

⁴ Unknown site includes ovary or fallopian tube [n=1]; ovary or omentum [n=1]; ovary, fallopian tube, or peritoneum [n=1]; and also includes diagnoses where ovary, fallopian tube, or peritoneum are favored primary site(s) but other site(s) cannot be ruled out [n=2].

⁵ Unknown timing represents cases that are unknown if diagnosis at or prior to baseline vs. post-baseline (i.e. incident case).

⁶ Includes omentum [n=2].

⁷ Unknown site includes reports of ovary or fallopian tube [n=4]; ovary or peritoneum [n=4]; fallopian tube or peritoneum [n=2]; ovary, fallopian tube, or peritoneum [n=5]; and also includes diagnoses where ovary, fallopian tube, or peritoneum are favored primary site(s) but other site(s) cannot be ruled out [n=4].

⁸ Race/ethnicity: precedence given to Hispanic ethnicity first, then Black race, then other race, then White race.

⁹ For those missing age at diagnosis [n=19], age was imputed as the midpoint of the range of plausible ages at diagnosis.

¹⁰ Medical confirmation of reported ovarian, fallopian tube, broad ligament, or peritoneal cancer is generally from pathology report but may include other medical documentation; National Death Index (NDI) Plus or death certificate confirmation is specific to cases that do not have medical confirmation.

¹¹ TNM stage at diagnosis is only available for cases with medical confirmation and is classified according to the American Joint Committee on Cancer (AJCC) 8th Edition Staging System.